Luohu District in Shenzhen will establish a national-level laboratory dedicated to recombinant protein research, aiming to accelerate the application of scientific and technological advancements in this field.

The involved parties will collaborate to establish an internationally influential industrial technology innovation platform for recombinant protein. They will also continue joint research efforts with various research institutes, such as the Chinese Academy of Sciences' Institute of Process Engineering, South China University of Technology's School of Life Sciences and Engineering, and Zhejiang University's School of Pharmacy, to develop a wider range of recombinant protein derivative products, ultimately benefiting a broader population.

Recombinant Protein: A Pioneering Field with High Potential

Synthetic biology, a field brimming with promise in modern science, underpins the development of recombinant proteins. This industry is characterized by high investment requirements and significant entry barriers.

Guangdong Medical Insurance Pharmaceutical Co., Ltd. stands out as a trailblazer in this field. They were the first to successfully restructure the conserved functional core regions of human type I and type III collagen.

This pioneering company holds the distinction of being the first research enterprise to introduce novel biological materials: type B recombinant humanized type I collagen and a recombinant type I collagen material incorporating lactoferrin and a transporter, both firsts in China.

These groundbreaking biological genetic proteins have been incorporated into the National Institutes of Health's (NIH) NCBI International Gene Protein Library in the United States, solidifying their position as domestic frontrunners.